ArticleJournal of gastrointestinal oncology2025
The SNHG3/miR-148a-3p axis-mediated high expression of DNMT1 is correlated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioengineered miR-148a-3p suppresses glycolysis and amino acid homeostasis in hepatocellular carcinoma cells by regulating multiple solute carrier transporters.Liver research (Beijing, China) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epigenetic reprogramming, particularly DNA methylation mediated by DNA-methyltransferase 1 (DNMT1), plays a crucial role in the pathogenesis of hepatocellular carcinoma (HCC). However, the regulatory mechanisms underlying DNMT1 overexpression and its relationship with immune infiltration in HCC remain unclear. This study aimed to investigate the expression pattern, prognostic significance, and regulatory network of DNMT1 in HCC, as well as its correlation with the tumor immune microenvironment. Methods: A pan-cancer analysis of DNMT1 expression and prognosis was conducted using The Cancer Genome Atlas (TCGA) data. A cohort of 102 pairs of HCC and adjacent normal tissues from patients who underwent surgical resection was analyzed by immunohistochemistry (IHC). Upstream regulatory non-coding RNAs (ncRNAs) were identified by bioinformatics analyses, including an expression correlation analysis, survival analysis, and competing endogenous RNA (ceRNA) network construction. The relationship between DNMT1 expression and immune cell infiltration was evaluated using multiple algorithms, including TIMER, CIBERSORT, and xCell. A Gene Set Enrichment Analysis (GSEA) was performed to identify the DNMT1-associated functional pathways. Results: DNMT1 was significantly overexpressed in the HCC tissues compared to the normal control tissues, and was correlated with poor overall survival (OS) and relapse-free survival (RFS). High DNMT1 expression was associated with advanced histological grade, elevated alpha-fetoprotein (AFP) levels, and older age (P<0.001). SNHG3 was confirmed to be an upstream long non-coding RNA (lncRNA) that competitively binds to hsa-miR-148a-3p, forming the SNHG3/hsa-miR-148a-3p/DNMT1 regulatory axis. DNMT1 expression was significantly positively correlated with the infiltration of multiple immune cell types, including B cells, CD8 Conclusions: The SNHG3/miR-148a-3p/DNMT1 axis represents a novel regulatory pathway in hepatocarcinogenesis. DNMT1 overexpression could serve as a biomarker for poor prognosis, and is closely associated with enhanced immune cell infiltration and immune checkpoint expression in HCC. These findings suggest that DNMT1 may serve as a potential therapeutic target for both conventional treatment and immunotherapy in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.